Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function

Young Hee Lee; Natalia Martin-Orozco; Peilin Zheng; Jing Li; Peng Zhang; Haidong Tan; Hyun Jung Park; Mira Jeong; Seon Hee Chang; Byung Seok Kim; Wei Xiong; Wenjuan Zang; Li Guo; Yang Liu; Zhong Jun Dong; Willem W. Overwijk; Patrick Hwu; Qing Yi; Larry Kwak; Zhiying Yang; Tak W. Mak; Wei Li; Laszlo G. Radvanyi; Ling Ni; Dongfang Liu; Chen Dong

doi:10.1038/cr.2017.90

Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function

Young Hee Lee, Natalia Martin-Orozco, Peilin Zheng, Jing Li, Peng Zhang, Haidong Tan, Hyun Jung Park, Mira Jeong, Seon Hee Chang, Byung Seok Kim, Wei Xiong, Wenjuan Zang, Li Guo, Yang Liu, Zhong Jun Dong, Willem W. Overwijk, Patrick Hwu, Qing Yi, Larry Kwak, Zhiying YangTak W. Mak, Wei Li, Laszlo G. Radvanyi, Ling Ni, Dongfang Liu, Chen Dong

Research output: Contribution to journal › Article › peer-review

225 Scopus citations

Abstract

The interaction between tumor and the immune system is still poorly understood. Significant clinical responses have been achieved in cancer patients treated with antibodies against the CTLA4 and PD-1/PD-L1 checkpoints; however, only a small portion of patients responded to the therapies, indicating a need to explore additional co-inhibitory molecules for cancer treatment. B7-H3, a member of the B7 superfamily, was previously shown by us to inhibit T-cell activation and autoimmunity. In this study, we have analyzed the function of B7-H3 in tumor immunity. Expression of B7-H3 was found in multiple tumor lines, tumor-infiltrating dendritic cells, and macrophages. B7-H3-deficient mice or mice treated with an antagonistic antibody to B7-H3 showed reduced growth of multiple tumors, which depended on NK and CD8⁺ T cells. With a putative receptor expressed by cytotoxic lymphocytes, B7-H3 inhibited their activation, and its deficiency resulted in increased cytotoxic lymphocyte function in tumor-bearing mice. Combining blockades of B7-H3 and PD-1 resulted in further enhanced therapeutic control of late-stage tumors. Taken together, our results indicate that the B7-H3 checkpoint may serve as a novel target for immunotherapy against cancer.

Original language	English (US)
Pages (from-to)	1034-1045
Number of pages	12
Journal	Cell research
Volume	27
Issue number	8
DOIs	https://doi.org/10.1038/cr.2017.90
State	Published - Aug 1 2017

Keywords

B7-H3
Checkpoint inhibition
Immunotherapy
Tumor immunity

ASJC Scopus subject areas

Molecular Biology
Cell Biology

MD Anderson CCSG core facilities

Flow Cytometry and Cellular Imaging Facility

Access to Document

10.1038/cr.2017.90

Cite this

Lee, Y. H., Martin-Orozco, N., Zheng, P., Li, J., Zhang, P., Tan, H., Park, H. J., Jeong, M., Chang, S. H., Kim, B. S., Xiong, W., Zang, W., Guo, L., Liu, Y., Dong, Z. J., Overwijk, W. W., Hwu, P., Yi, Q., Kwak, L., ... Dong, C. (2017). Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function. Cell research, 27(8), 1034-1045. https://doi.org/10.1038/cr.2017.90

Lee, YH, Martin-Orozco, N, Zheng, P, Li, J, Zhang, P, Tan, H, Park, HJ, Jeong, M, Chang, SH, Kim, BS, Xiong, W, Zang, W, Guo, L, Liu, Y, Dong, ZJ, Overwijk, WW, Hwu, P, Yi, Q, Kwak, L, Yang, Z, Mak, TW, Li, W, Radvanyi, LG, Ni, L, Liu, D & Dong, C 2017, 'Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function', Cell research, vol. 27, no. 8, pp. 1034-1045. https://doi.org/10.1038/cr.2017.90

@article{65a9534e5089449c842dc4d340f41252,

title = "Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function",

abstract = "The interaction between tumor and the immune system is still poorly understood. Significant clinical responses have been achieved in cancer patients treated with antibodies against the CTLA4 and PD-1/PD-L1 checkpoints; however, only a small portion of patients responded to the therapies, indicating a need to explore additional co-inhibitory molecules for cancer treatment. B7-H3, a member of the B7 superfamily, was previously shown by us to inhibit T-cell activation and autoimmunity. In this study, we have analyzed the function of B7-H3 in tumor immunity. Expression of B7-H3 was found in multiple tumor lines, tumor-infiltrating dendritic cells, and macrophages. B7-H3-deficient mice or mice treated with an antagonistic antibody to B7-H3 showed reduced growth of multiple tumors, which depended on NK and CD8+ T cells. With a putative receptor expressed by cytotoxic lymphocytes, B7-H3 inhibited their activation, and its deficiency resulted in increased cytotoxic lymphocyte function in tumor-bearing mice. Combining blockades of B7-H3 and PD-1 resulted in further enhanced therapeutic control of late-stage tumors. Taken together, our results indicate that the B7-H3 checkpoint may serve as a novel target for immunotherapy against cancer.",

keywords = "B7-H3, Checkpoint inhibition, Immunotherapy, Tumor immunity",

author = "Lee, {Young Hee} and Natalia Martin-Orozco and Peilin Zheng and Jing Li and Peng Zhang and Haidong Tan and Park, {Hyun Jung} and Mira Jeong and Chang, {Seon Hee} and Kim, {Byung Seok} and Wei Xiong and Wenjuan Zang and Li Guo and Yang Liu and Dong, {Zhong Jun} and Overwijk, {Willem W.} and Patrick Hwu and Qing Yi and Larry Kwak and Zhiying Yang and Mak, {Tak W.} and Wei Li and Radvanyi, {Laszlo G.} and Ling Ni and Dongfang Liu and Chen Dong",

year = "2017",

month = aug,

day = "1",

doi = "10.1038/cr.2017.90",

language = "English (US)",

volume = "27",

pages = "1034--1045",

journal = "Cell research",

issn = "1001-0602",

publisher = "Nature Publishing Group",

number = "8",

}

TY - JOUR

T1 - Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function

AU - Lee, Young Hee

AU - Martin-Orozco, Natalia

AU - Zheng, Peilin

AU - Li, Jing

AU - Zhang, Peng

AU - Tan, Haidong

AU - Park, Hyun Jung

AU - Jeong, Mira

AU - Chang, Seon Hee

AU - Kim, Byung Seok

AU - Xiong, Wei

AU - Zang, Wenjuan

AU - Guo, Li

AU - Liu, Yang

AU - Dong, Zhong Jun

AU - Overwijk, Willem W.

AU - Hwu, Patrick

AU - Yi, Qing

AU - Kwak, Larry

AU - Yang, Zhiying

AU - Mak, Tak W.

AU - Li, Wei

AU - Radvanyi, Laszlo G.

AU - Ni, Ling

AU - Liu, Dongfang

AU - Dong, Chen

PY - 2017/8/1

Y1 - 2017/8/1

N2 - The interaction between tumor and the immune system is still poorly understood. Significant clinical responses have been achieved in cancer patients treated with antibodies against the CTLA4 and PD-1/PD-L1 checkpoints; however, only a small portion of patients responded to the therapies, indicating a need to explore additional co-inhibitory molecules for cancer treatment. B7-H3, a member of the B7 superfamily, was previously shown by us to inhibit T-cell activation and autoimmunity. In this study, we have analyzed the function of B7-H3 in tumor immunity. Expression of B7-H3 was found in multiple tumor lines, tumor-infiltrating dendritic cells, and macrophages. B7-H3-deficient mice or mice treated with an antagonistic antibody to B7-H3 showed reduced growth of multiple tumors, which depended on NK and CD8+ T cells. With a putative receptor expressed by cytotoxic lymphocytes, B7-H3 inhibited their activation, and its deficiency resulted in increased cytotoxic lymphocyte function in tumor-bearing mice. Combining blockades of B7-H3 and PD-1 resulted in further enhanced therapeutic control of late-stage tumors. Taken together, our results indicate that the B7-H3 checkpoint may serve as a novel target for immunotherapy against cancer.

AB - The interaction between tumor and the immune system is still poorly understood. Significant clinical responses have been achieved in cancer patients treated with antibodies against the CTLA4 and PD-1/PD-L1 checkpoints; however, only a small portion of patients responded to the therapies, indicating a need to explore additional co-inhibitory molecules for cancer treatment. B7-H3, a member of the B7 superfamily, was previously shown by us to inhibit T-cell activation and autoimmunity. In this study, we have analyzed the function of B7-H3 in tumor immunity. Expression of B7-H3 was found in multiple tumor lines, tumor-infiltrating dendritic cells, and macrophages. B7-H3-deficient mice or mice treated with an antagonistic antibody to B7-H3 showed reduced growth of multiple tumors, which depended on NK and CD8+ T cells. With a putative receptor expressed by cytotoxic lymphocytes, B7-H3 inhibited their activation, and its deficiency resulted in increased cytotoxic lymphocyte function in tumor-bearing mice. Combining blockades of B7-H3 and PD-1 resulted in further enhanced therapeutic control of late-stage tumors. Taken together, our results indicate that the B7-H3 checkpoint may serve as a novel target for immunotherapy against cancer.

KW - B7-H3

KW - Checkpoint inhibition

KW - Immunotherapy

KW - Tumor immunity

UR - http://www.scopus.com/inward/record.url?scp=85026672802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026672802&partnerID=8YFLogxK

U2 - 10.1038/cr.2017.90

DO - 10.1038/cr.2017.90

M3 - Article

C2 - 28685773

AN - SCOPUS:85026672802

SN - 1001-0602

VL - 27

SP - 1034

EP - 1045

JO - Cell research

JF - Cell research

IS - 8

ER -

Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function

Abstract

Keywords

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Fingerprint

Cite this